91-105 of 266
Efgartigimod Shows Early Promise for Primary Sjögren’s Disease
Living RheumEfgartigimod Shows Early Promise for Primary Sjögren’s Disease
Unmasking Patient Subtypes in Sjögren’s Disease to Enable Personalized Care
Living RheumUnmasking Patient Subtypes in Sjögren’s Disease to Enable Personalized Care
Translating Patisiran’s 6-Minute Walk Test Gains into Real-Life Impact in ATTR-CM
Heart MattersTranslating Patisiran’s 6-Minute Walk Test Gains into Real-Life Impact in ATTR-CM
Staging the Benefit: Tafamidis Outcomes in ATTR-CM Depend on Timing
Heart MattersStaging the Benefit: Tafamidis Outcomes in ATTR-CM Depend on Timing
Analyzing Outpatient Worsening Heart Failure in ATTR-CM
Heart MattersAnalyzing Outpatient Worsening Heart Failure in ATTR-CM
Current and Emerging Treatments for Transthyretin Amyloid Cardiomyopathy
Heart MattersCurrent and Emerging Treatments for Transthyretin Amyloid Cardiomyopathy
- advertisement
Shared Decision-Making in Transthyretin Amyloid Cardiomyopathy Care
Heart MattersShared Decision-Making in Transthyretin Amyloid Cardiomyopathy Care
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
Project Oncology®SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
Impact of DLL3-Directed Immunotherapy on the Small Cell Lung Cancer Landscape
Project Oncology®Impact of DLL3-Directed Immunotherapy on the Small Cell Lung Cancer Landscape
Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
Project Oncology®Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
Project Oncology®The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
Diagnosing LCNEC of the Lung: Challenges and Strategies
Project Oncology®Diagnosing LCNEC of the Lung: Challenges and Strategies
- advertisement
Personalizing Care for Large Cell Neuroendocrine Carcinoma
Project Oncology®Personalizing Care for Large Cell Neuroendocrine Carcinoma
Pediatric Sickle Cell Disease: Analyzing Trends in Medication Utilization
Project Oncology®Pediatric Sickle Cell Disease: Analyzing Trends in Medication Utilization
Exploring Circulating CD34+ Cells as a Biomarker of Fracture Risk in DMD
NeuroFrontiersExploring Circulating CD34+ Cells as a Biomarker of Fracture Risk in DMD





































